Stakeholders: More FDA Involvement Needed In Generic Supply Chain

The third iteration of the Generic Drug User Fee Amendments should allocate more funding for overseas FDA inspections and postmarket surveillance because the quality of generic drugs has a direct effect on the U.S. drug supply chain and patient safety, regulatory experts told a panel of FDA officials on Tuesday (July 21). Kaiser Permanente’s senior vice president of government relations, Anthony Barrueta, said ensuring product quality and a stronger supply chain should be high priorities for the next round of...